Blood Stream Infections (BSI) are major causes of morbidity and mortality in burn patients (
1). Microorganisms responsible for BSI are generally bacteria; however,
Candida spp. are the infection agents in as many as 8% of all cases (
2). Burn wound colonization and infections are generally the first steps to systemic infection (
1). Candidemia in burn patients has been associated with high mortality and a prolonged hospital stay (
3,
4). Disruption of skin barrier in burn is a major risk factor for invading fungi. The necrotic tissue resulting burn injury is an excellent medium for colonizing and growing various microorganism including fungi. Administration of broad-spectrum antibiotics, glucocorticosteroid treatment, mechanical ventilation, parenteral nutrition, trachstomy tubing, burn-induced hyperglycemia, renal failure, persistent neutropenia, immune dysfunction, multiple sites of colonization, and hemodialysis and prolonged hospital stay are also thought to be predisposing factors for candidemia (
5-
7).
Candidaalbicans has been described as the most common cause of candidemia. However, the number of non-albicans species has increased during recent decades, and
C. glabrata has emerged as the second most common cause, followed by
C.parapsilosis,
C. tropicalis and
C. krusei (
8). The latest study about candidemia in Iran unexpectedly revealed the higher rate of
C. parapsilosis (34.4%), followed by
C. glabrata (28.1%) and
C. albicans (25%). The predisposing factor in these patients was surgery, cancer, hematological malignancy, diabetes, renal filature, premature birth and pancreatitis. Voriconazole was the most active drug and fluconazole was associated with high Minimum Inhibitory Concentration (MIC) results (
9). Reduced susceptibility of non-
albicans Candida species to antifungal agents has been reported (
10,
11). It is known that
C. glabrata exhibits intrinsically low susceptibility to azoles and develops resistance after exposure to these drugs (
12). Inherent and emerging resistance to antifungal agents represents a major challenge for empirical therapeutic and prophylactic strategies (
13).
Effective therapeutic management of patients with candidemia requires early identification of the infecting agent. Appropriate antifungal therapy guided by antifungal susceptibility testing improves the outcome for severely injured burn victims susceptible to fungal infection. In Iran, there is a lack of extensive studies regarding candidemia in burn and the antifungal susceptibility patterns of the isolated Candida strains.